Enzon Pharmaceuticals Inc  

(Public, NASDAQ:ENZN)   Watch this stock  
Find more results for ENZN
-0.028 (-6.47%)
Real-time:   3:41PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.40 - 0.42
52 week 0.40 - 1.88
Open 0.41
Vol / Avg. 153,075.00/323,417.00
Mkt cap 15.99M
P/E 1.19
Div/yield 0.25
EPS 0.34
Shares 44.18M
Beta 0.85
Inst. own 52%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -47.25% 92.37%
Operating margin -24.12% 92.36%
EBITD margin - 92.36%
Return on average assets -23.21% 136.60%
Return on average equity -41.45% 165.21%
Employees 1 -
CDP Score - -


20 Kingsbridge Rd
PISCATAWAY, NJ 08854-3919
United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company is dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. The Company receives royalty revenues on seven marketed products that utilize its Customized PEGylation Linker Technology (Customized Linker Technology) platform, namely PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. PEGINTRON is a PEG-enhanced version of Merck’s alpha interferon product, INTRON A, which is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Sylatron is approved for the adjuvant treatment of melanoma. Macugen (pegaptanib sodium injection) is being marketed by Valeant and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.

Officers and directors

Jonathan N. Christodoro Chairman of the Board
Age: 39
Bio & Compensation  - Reuters
George W. Hebard III Interim Principal Executive Officer and Interim Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
Richard L. Feinstein Principal Financial Officer, Vice President - Finance
Age: 71
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Director
Age: 40
Bio & Compensation  - Reuters
Jennifer I. McNealey Director
Age: 41
Bio & Compensation  - Reuters